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Summary A colorectal tumour-directed immunotoxin, ICI D0490, has been constructed by linking recom-
binant ricin A-chain to C242, a mouse monoclonal antibody, by means of a methyl-hindered disulphide bond.
Recombinant ricin A-chain and a hindered disulphide linker were anticipated to confer favourable phar-
macokinetic properties on the immunotoxin. The pharmacokinetics of ICI D0490 have been studied in mice
following single and repeated iv administration. The concentrations of intact immunotoxin in mouse plasma at
various time intervals after injection for up to 96 h were measured by a solid-phase enzyme-linked immunosor-
bant assay (ELISA) and the data analysed by both model-dependent (two compartment) and model-
independent methods. Following a single iv bolus dose of 2.5 mg kg-' (50% of the LDIO in mice), the
clearance of ICI D0490 from the plasma was extremely slow; 34 tlI min'- kg-', t'2P = 33 h. Model-dependent
and model-independent analyses gave comparable results with steady state volumes of distribution of 93 and
69 ml kg-', respectively. The two compartment analysis gave an initial volume of distribution (63 ml kg-')
which is consistent with the predicted plasma volume. Over the dose range 0.05 -5 mg ICI D0490 kg ', plasma
levels at 2 and 24 h were linearly related to dose (r > 0.98) indicating that at doses up to 5 mg ICI D0490 kg-'
clearance does not appear to have a saturable component. Repeated doses of ICI D0490 (1 mg kg- day x 5)
did not lead to drug accumulation. These studies demonstrate that ICI D0490 has excellent in vivo stability
and persistence which, in conjunction with activity and toxicity data, identify ICI D0490 as a promising
candidate for clinical evaluation in the treatment of colorectal cancer.
Immunotoxins are conjugates of antibodies, or antibody
fragments, with protein toxins, usually of plant or bacterial
origin. Several recent reviews have been published which
cover the background to and potential use of immunotoxins
(Baldwin & Byers, 1987; Fitzgerald & Pastan, 1989; Vitteta &
Thorpe, 1991; Wawrzynczak, 1991). In recent years, much
research has been undertaken in an attempt to perfect
immunotoxins for clinical use and, of those evaluated in the
clinic, most have incorporated ricin A-chain as the toxin.
This plant toxin is a potent inhibitor of protein synthesis
which acts by catalytically removing an adenine moiety from
the 28S ribosomal subunit (Endo et al., 1987; Endo &
Tsurugi, 1987). The original ricin A-chain conjugates that
were developed utilised native, plant-derived, ricin A-chain
and this was found to be responsible, in part, for the rapid
plasma clearance of the immunoconjugate. Rapid clearance is
due to hepatic recognition of carbohydrate residues that are
abundantly present on native ricin A-chain (Blakey &
Thorpe, 1986; Bourrie et al., 1986; Byers et al., 1987). Use of
a deglycosyl or aglycosyl toxin substantially reduces initial
immunotoxin clearance from the plasma without compromis-
ing cytotoxic potency (Blakey et al., 1987; 1988; Trown et al.,
1991; Wawrzynczak et al., 1990; 1991a; 1991b).
The second factor influencing immunotoxin peristence in
vivo is the stability of the disulphide bond linking the toxin
and the antibody. Rapid in vivo cleavage of an immunotoxin
is disadvantageous both because it reduces the duration of
tumour cell exposure to active agent and because the free
antibody released can theoretically compete with immuno-
toxin for binding to the target antigen. Steric hindrance of
the disulphide bond produces stabilisation of the conjugate
to reduction by free thiols, for example glutathione, which
results in a prolongation of the P-phase of immunotoxin
pharmacokinetics, without reducing antigen binding or toxin
potency (Thorpe et al., 1988; 1987; Worrell et al., 1986).
Data generated by pharmacokinetic modelling have shown
that, for good immunotoxin or antibody tumour penetration,
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a long plasma half life may be at least as beneficial as a high
antigen density or antibody binding affinity (Fujimori et al.,
1989; Sung et al., 1990).
Several immunotoxins have entered into clinical studies
(Byers et al., 1989; Gould et al., 1989; Hertler et al., 1988;
Pai et al., 1991; Spitler et al., 1987; Vitetta et al., 1991;
Weiner et al., 1989). However, success in patients has been
disappointing. The problems that have been encountered in-
clude poor tumour specificity of the conjugate resulting in
antibody-directed normal tissue toxicity (Gould et al., 1989;
Pai et al., 1991) and immunotoxin-induced capillary leak
syndrome, observed in nearly all studies. In addition, where
acceptable patient tolerance of immunotoxins has been
achieved, no consistent anti-tumour activity has been
observed with the exception of a pan B-cell-directed ricin
A-chain immunotoxin for the treatment of B-cell lymphoma
(Vitetta et al., 1991).
In the light of the above clinical and preclinical inform-
ation, ICI D0490 has been conceived for the treatment of
colorectal cancer. Aglycosyl recombinant ricin A-chain was
selected as the toxin moiety, with the aim of reducing initial
clearance, and a methyl-hindered disulphide coupling agent,
N-succinimidyl 3-(2-pyridyldithio)-3-methylproprionate, was
used with the aim of prolonging in vivo persistence. In the
construction of ICI D0490 a tumour selective antibody, C242
(Larson et al., 1988; Kuusela et al., 1991), was selected. This
antibody shows binding to >65% of the 200 colorectal
tumour samples examined to date by immunoperoxidase
staining (Wright et al., 1992). The C242 antibody binds to
the CA242 antigen (Baeckstrom et al., 1991) which is
associated with the high molecular weight mucous-
glycoprotein CANAG (cancer-antigen).
This paper reports the pharmacokinetic characteristics of
ICI D0490 in non-tumour bearing mice after intravenous
administration. These studies were performed in order to
investigate whether or not the pharmacokinetic advantages
anticipated by the use of a hindered disulphide linker and
recombinant ricin A-chain had been achieved. The dose and
schedule dependence of ICI D0490 pharmacokinetics have
been investigated with a view to identifying, along with
efficacy data, an optimal regime and dose escalation scheme
for early clinical trials.
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Materials and methods
Six 8 week old female Balb/c mice from the Comparative
Biology Centre, University of Newcastle upon Tyne were
used for these experiments. Food and water were available ad
libitum throughout the studies. For the ELISA,2,2'-amino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS), casein,
rabbit anti-ricinus communis and rabbit-anti-goat IgG-HRP
were obtained from Sigma Chemical Co, Poole, Dorset, UK.
Goat-anti-mouse IgG (Fc fragment) was obtained from ICN
Immunobiochemicals, California, USA.
C242-ricin A-chain conjugation andpreparation ofpurified ICI
D0490
C242 antibody (IgGI) which reacts with the CANAG antigen
was originally described by Larson et al. (1988). Recom-
binant ricin A-chain was obtained from the cDNA corres-
ponding to the ricin gene originally supplied by Prof J.M.
Lord, University of Warwick, Coventry, UK. Immunotoxin
was prepared at ICI Pharmaceuticals using the methyl-
hindered coupling reagent N-succinimidyl 3-(2-pyridyldithio)-
3-methylproprionate (Worrell et al., 1986) and recombinant
ricin A-chain. The conjugation process was essentially as
described previously by Thorpe et al. (1988). ICI D0490 was
purified to remove antibody and free ricin A-chain using size
exclusion (Sephacryl S-300) and triazine dye affinity
chromatography. Any unmodified linker residues were 'cap-
ped' by reaction with L-cysteine. Polyacrylamide gel analysis
and capillary zone electrophoresis demonstrated that the
immunotoxin contained less than 1% free antibody and con-
sisted predominantly of two major and equal components
with molecular weights of 180 kDa and 210 kDa, correspon-
ding to one molecule of antibody linked to one and two
molecules of ricin A-chain, respectively. Endotoxin levels
were consistently less than 1 unitml-.
Preliminary toxicity studies
To enable appropriate doses of ICI D0490 to be used in the
pharmacokinetic studies, the maximum tolerated dose was
defined in mice. Groups of 5-10 mice, ten for the lower
doses and five for the higher doses, received single bolus iv
doses of ICI D0490 ranging from 0.5 mg kg-' to 6mgkg-'
and animals were monitored closely for 21 days. Mice were
killed if their body weight declined by more than 20% or if
otherwise clinically indicated. LDIo values, with 95%
confidence limits, were calculated by probit analysis.
Pharmacokinetics ofICI D0490following iv administration
To define the pharmacokinetics of ICI D0490 in detail, mice
were dosed intravenously after briefly warming the tail in
water at 45°C. A dose of 2.5 mg ICI D0490kg-' in an
injection volume of 0.1 ml g-' was administered and the time
was recorded accurately. At 4, 7, 11, 17, 23, 29, 45 and
58 min, and 2, 3, 4, 8, 24, 48, 72 and 96 h thereafter, mice
(four animals per group) were killed by CO2 asphyxiation,
the thorax opened and a blood sample was taken directly
from the left ventricle of the heart into syringes pre-rinsed
with heparin (100 units ml-Iin saline). Plasma was prepared
by centrifugation at room temperature and diluted 1:200
(v:v) directly into ELISA assay blocking buffer (see below).
Plasma concentrations ofimmunotoxin were quantified by an
ELISA method (see below) and the concentration vs time
data generated were analysed by both model-dependent and
model-independent pharmacokinetic methods. The model-
dependent method utilised a two compartment open model
as described by the equation:
Ct = Ae-' + Be-t
where Ct is the plasma ICI D0490 concentration at time t, a
and P are the first order rate constants for the first and
second phases ofplasma clearance and A and B are concent-
ration constants. The equation was fitted to the data by
non-linear least squares regression analysis using a weighting
of I/Y2 (GraphPAD InPlot, GraphPAD Software, San
Diego, USA). For the model-dependent analysis, microscopic
rate constants, the volume of the central compartment (VI),
volume of distribution at steady state (Vdss), clearance and
area under the plasma concentration v. time curve (AUC)
were calculated from the fitted values ofA, a, B and P using
standard equations (Welling, 1986). For the model indepen-
dent analysis the area under the curve (AUC) was calculated
by the trapezoidal rule, the clearance from the equation,
clearance = dose/AUC and the volume of distribution as:
Vdss = dose[AUMCO0,j]/[AUCO0 ]2
where AUMCO.,,, is the area under the curve of the product
of time and plasma concentration from time zero to infinity
(Welling, 1986).
Effect ofadministered dose on thepharmacokinetics ofiv ICI
D0490
Groups of five mice were treated with a single intravenous
dose of ICI D0490 of 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2.5 or
5 mgkg-'. ICI D0490 was diluted in normal saline and given
in a volume of 0.1 ml 10 g-'. In a pilot experiment (data not
shown) it was shown that the concentration of ICI D0490 (as
measured by the ELISA method) in blood taken from the tail
vein was equivalent to that collected directly from the heart
of the same animal. Thus, these mice had blood samples
taken from the tail vein at 2 and 24 h after administration.
Plasma samples were prepared as described above for ICI
D0490 analysis by ELISA.
Effect ofrepeat administration on theplasma levels ofICI
D0490
In addition to single dose studies, the effect of repeat int-
ravenous dosing of ICI D0490 on the plasma levels of the
drug were investigated. The total dose was constant and
three schedules were compared: a single dose of Smgkg-',
I mgkg-'/day x 5 and 1.67 mg kg-' on days 1, 3 and 5.
Groups of five mice received ICI D0490 diluted in normal
saline at a volume of 0.1 ml Og-'. Blood samples (70ftl volume) were collected from the tail vein at 2, 24 and 48 h
after the initial dose, and at further time points for the repeat
dosing schedules, and analysed for ICI D0490 levels by
ELISA.
ELISAfor ICID0490 in biologicalfluids
An ELISA (enzyme-linked immunosorbant assay) developed
at ICI Pharmaceuticals was used to quantify ICI D0490
concentrations in plasma. All buffers used in this assay were
freshly prepared for each assay run. Nunc certificated 96 well
plates were coated with 100fil of rabbit anti-ricinus communis
(15fgml-') in 0.5 M sodium phosphate pH 7.4 buffer,
hereafter referred to as phosphate buffer, per well. The plates
were left for a minimum of 4 h at 4°C and then washed five
times with an excess of phosphate buffer containing 0.05%
(w/v) Tween-80 (wash buffer). The plates were then blocked
with phosphate buffer containing casein at 0.05% (w/v)
(blocking buffer). After one hour the plates were rinsed as
before with wash buffer. Standards were prepared at 0.05 to
25pg ICI D0490 ml-'in control mouse plasma (equivalent
to 5 ILI of plasma/well) and diluted 1:200 (v:v) in blocking
buffer and 1001tl standard or unknown sample added to each
well. Plates were then left at room temperature overnight,
washed as above, and goat anti-mouse Fc directed antibody
(1:10,000 dilution of material supplied by the manufacturer)
added in blocking buffer for a 4 h incubation period at room
temperature. After a further wash cycle, the second layer
antibody, rabbit anti-goat conjugated to horseradish perox-
idase (1:3750 dilution) was added in 100gil blocking buffer to
each well for a further overnight incubation at room
temperature. Finally, the colour reaction was initiated by
addition of 100pl of 1 mg ABTS ml-'in acetate buffer at
pH 4.2 containing hydrogen peroxide (0.013%, v/v). When1312 J.A. CALVETE et al.
the standard equivalent to 1.6pg ICI D0490 ml' in plasma
reached an optical density of 0.7 at 405 nm, the reaction was
stopped by the addition of 100tl1OmM aqueous sodium
azide to each well and the plates read on a Dynatech
MR7000 plate reader at 405 nm. Standard curves equivalent
to 0.05 to 25iLgICI D0490 ml-' plasma were generated using
a 5-parameter fit available on MULTICALC software (Wal-
lac Oy, Software), and values calculated for unknown sam-
ples, each of which was analysed in triplicate. During the
experiments described in the present paper, 'within day' and
'between day' coefficients of variation for quality assurance
samples at 0.5 lAg ICI D0490ml' plasma were <5% and
8%, respectively. The assay was most precise in the mid-
range of the standard curve and consequently values were
only used from this region. Plasma samples were diluted in
series to ensure that a value in the accurate range of the
curve was obtained.
Results
Preliminary toxicity studies
Mice received a single iv bolus dose of ICI D0490 and were
monitored for signs of toxicity. Adverse effects were
manifested as body weight loss and hypokinesia. The LDIO
was defined as a single dose of 5.4 mg kg-' (95% limits
4.9-5.8 mg kg-'). The lethal toxicity was delayed for about
three days after dosing which enabled a single dose of
5 mgkg' to be safely administered for characterisation of
initial plasma levels of ICI D0490. For longer time points,
50% of the LDIO (2.5 mg kg-') was the maximum dose
studied.
Pharmacokinetics ofICI D0490following i.v. administration
After a single intravenous dose of 2.5 mg kg', ICI D0490
could be detected in the plasma of mice at all of the time
points studied from 4 min to 96 h (Figure 1). The AUC,
clearance and volume of distribution were calculated from
the data using model-independent calculations and these
values were compared to the values obtained when the data
were fitted to a two compartment open model, (Table I). The
model-dependent and independent analyses gave comparable
results and hence the use of a two compartment model is
appropriate. Notably, the clearance of ICI D0490 from the
plasma was extremely slow (34psl min- kg-') and the P-
phase half life was long (33 h). For the model dependent
pharmacokinetic analysis, AUC is calculated as:
AUC = A/a + B/P
E 40
CD
c 30
0
E 20 U'
Table I Pharmacokinetic parameters for ICI D0490 in Balb/c mice
following an iv bolus dose of 2.5 mg kg-'
Model independent Model dependent
AUC (mgml-'min-a 75 73
Clearance (il min' kg-' 33 34
Vdss (ml kg-') 69 93
VI (ml kg-') - 63
t'ha (h) - 2.8
t%P (h) - 33
klo (min-') - 5.5 x 10-4
k12 (min- ) - 1.3 x 10-3
k2, (minm ') 2.6 x 10-3
aModel-independent and dependent pharmacokinetic parameters
were derived as described in Materials and methods.
Thus, the contribution of the a-phase to total ICI D0490
AUC can be calculated as A/a. The value so obtained,
3.9 mg ml-' min-', in comparison to the total AUC,
73 mg ml-' min-' (Table I), reveals at the x-phase cont-
ributes only 5% of the total ICI D0490 AUC, another
indication of the limited initial clearance of the immunotoxin.
The calculated volume of the central compartment
(63 ml kg-') is consistent with VI being the plasma volume
whilst the volume of distribution of ICI D0490 at steady
state (93 ml kg-') did not reach that of the calculated extra-
cellular fluid volume, indicating little tissue penetration of the
immunotoxin.
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Figure 1 Plasma ICI D0490 levels in mice following an iv bolus
dose of 2.5 mg kg-'. Each point is the mean ± s.d. of data from
four mice. The line (r = 0.98) is that given by non-linear least
squares fitting of a bi-exponential equation to the concentration
vs time data as described in Materials and methods.
Figure 2 Relationship between ICI D0490 dose and plasma
levels 2 h a and 24 h b after administration. Each point is the
mean of data from five mice. The lines are those given by linear
regression analysis following logarithmic transformation of both
the concentration and administered dose data.PHARMACOKINETICS OF ICI D0490 1313
Table II The effect of administration schedule on plasma levels of ICI D0490
Time after ICI D0490 administration
Dose and schedule Day 2h 24 h 48h
I mg kg-' day' x 5 1 12.0 2.la 6.3 2.6 NDb
3 10.4±2.8 5.5±1.8 ND
5 7.8 0.2 4.6 0.9 ND
1.67 mg kg-' day-' x 3 1 13.9 ± 3.8 6.3 ± 3.4 2.4 ± 0.5
3 12.6 1.6 ND 2.5 0.5
5 11.8 1.6 4.5 0.8 ND
5 mg kg-' single 1 12.7 3.0 5.4 2.2 1.9 ± 0.9
aPlasma concentration of ICI D0490 (jig ml-'). to allow direct comparison plasma levels
have been normalised to I mg kg-'. ie: data for the x 3 and single dose schedules have
been divided by 1.67 and 5, respectively. Data are the mean ± s.d. of observations from
five mice.
bND = Not determined.
Effect ofadministered dose on the pharmacokinetics ofICI
D0490 dosed iv
To investigate the effect of dose on the pharmacokinetics of
ICI D0490, plasma levels were measured at limited, represen-
tative, time points (2 and 24 h) following doses ranging from
the LDIo to 1/1000th LD,O. As shown in Figure 2, there was
a good correlation between ICI D0490 dose and plasma
concentrations at both time points and the slope of the
relationships, when both concentration and dose data were
logarithmically transformed, was unity (2 h = 0.99 ± 0.04;
24 h = 1.02 ± 0.07, mean ± SE). ICI D0490 could only be
detected at 2 h following doses of 0.005 and 0.01 mg kg-'.
Hence the data obtained from this study indicate that the
pharmacokinetics of ICI D0490 are linearly related to dose
over at least a 100-fold range of doses from 0.05 mg kg-' to
Smgkg-'.
Effect ofrepeated administration on theplasma levels ofICI
D0490
To investigate possible alterations in ICI D0490 clearance
following repeated administration, a single iv bolus dose of
5mgkg-' was compared to 1mgkg' day-' x 5 and
1.67 mg kg-' given on days 1, 3 and 5. As shown in Table II,
no accumulation of ICI D0490 in the plasma over the period
studied was seen at these dose levels. This is surprising since
following a single dose of 2.5 mg kg-' the concentration of
ICI D0490 in the plasma at 24 h (15fg ml-') was 37% of the
extrapolated concentration at time zero (Figure 1). Normalis-
ing the data to a dose of 1 mg kg-', this is equivalent to
5.6 ytgml-' which is within the observed range of ICI D0490
plasma levels 24 h after the first dose of 1 mg kg-'
(6.3 ± 2.6jigml1', Table II). However, on repeated dosing at
1 mgkg' no accumulation of ICI D0490 was observed. If
anything, 2 h plasma levels appear to be lower following
repeated administration of ICI D0490 (Table II). Taken
together, the lack of ICI D0490 accumulation over 5 days
and the apparent decrease in plasma levels at 2 h suggests
that plasma clearance of the immunotoxin may be induced
by repeated administration.
Discussion
The experiments reported here show that ICI D0490 has
favourable pharmacokinetic properties when administered
intravenously to mice. Following a single iv dose of 2.5 mg
ICI D0490 kg- plasma levels could be fitted to a two com-
partment open model without distortion of the data. There
was little initial clearance from the plasma and a relatively
long ox-phase half-life was observed. The volume of the cent-
ral compartment approximates to that of the plasma volume
in mice and hence during the initial 2 h period there is very
little distribution of ICI D0490 from the plasma. In the light
of earlier studies, the reduced initial clearance of ICI D0490
is probably a reflection of the aglycosyl nature of the recom-
binant ricin A-chain moiety of the immunotoxin (Thorpe et
al., 1988; Trown et al., 1991; Wawrzynczak et al., 1991b).
The second notable feature of the pharmacokinetics of ICI
D0490 is the long elimination phase half-life of 33 h. To our
knowledge, this is the longest P-phase half life so far reported
for an immunotoxin in rodents and this property is
presumably a reflection of the stable disulphide linker moiety
of the ICI D0490. This is consistent with the findings of
Thorpe and colleagues who demonstrated that, whilst the
a-phase half life and plasma clearance were heavily
influenced by A-chain glycosylation, the P-phase half life is a
function of steric hindrance to cleavage of the disulphide
bond (Thorpe et al., 1988). Similar results were obtained by
Worrell et al. (1986) and these latter authors developed the
methyl-hindered linker used in the construction of ICI
D0490. The potential importance of a long P-phase half life
for immunotoxins has recently been underlined by modelling
studies which suggest that half life can be an important as
antibody binding affinity as a determinant of tumour
localisation (Sung et al., 1990). Furthermore, in their pre-
clinical study, Thorpe et al. (1988) demonstrated that
immunotoxins with a methyl-hindered linker had greater
antitumour activity, when given as an equimolar dose, than
immunotoxins with unhindered linkers.
In summary, for ICI D0490, both limited initial clearance
and a prolonged P-phase half-life contribute to good plasma
persistence and hence prolonged exposure of tumour cells to
immunotoxin. Prolonged exposure of tumours should in turn
aid penetration of ICI D0490 and hence maximise the
likelihood of antitumour activity. However, it should be
noted that the CA242 antigen is not expressed in mouse
tissues and hence any influence of tissue CA242 levels on the
pharmacokinetics of ICI D0490 would not have been
detected in the experiments described here. Studies of the
pharmacokinetics of ICI D0490 in nude mice bearing CA242
positive and negative human tumour xenografts are under
way and preliminary results indicate no major differences.
Following a dose of 50% of the LDIo, the plasma levels of
ICI D0490 were sustained at over 20jigml-' for 8 h and at
over 1 jgml-' for 96 h (Figure 1). This latter concentration
is in excess of the level required in vitro to produce greater
than 99.9% cell kill in a clonogenic assay using either
CoLo201 or CoLo2O5 human colorectal tumour cells. Fur-
thermore, 2.5 mg ICI D0490 kg-' is a dose that gives long
growth delays (> 30 days) in a nude mouse xenograft model
with the CoLo201 tumour that expresses the CA242 antigen
(J. Calvete, unpublished results). However, no anti-tumour
activity with this dose of ICI D0490 was observed against
xenograft tumours not expressing CA242 antigen.
When a wide range of single doses of ICI D0490 was
studied it was evident that there was a linear relationship
between the dose given and plasma levels achieved, at 2 and
24h, time points that reflect both phases of immunotoxin
clearance. Thus, the pharmacokinetics of a low dose of ICI
D0490 should allow the prediction of doses required to
achieve target plasma levels. Dose escalation in early clinical
trials, on the basis of plasma level data, has been widely
advocated for cytotoxic drugs (Newell, 1990) although the1314 J.A. CALVETE et al.
role of this approach in studies with immunotoxins remains
unclear. Given the limitations of preclinical toxicity models,
initial doses of immunotoxins in Phase I trials should be
conservative. However, once initial safety is established, dose
escalation should be performed as quickly as possible. With
an understanding of the immunotoxin concentrations
required for in vitro cytotoxicy, and the plasma levels seen in
mice following administration of therapeutic doses, it may be
possible to guide dose escalation in patients. Whilst attrac-
tive, pharmacokinetically-guided dose escalation can only be
attempted if a linear relationship exists between dose given
and plasma level achieved. On the basis of the results pres-
ented in Figure 2, the pharmacokinetics of ICI D0490 would
appear to be linearly related to dose and hence phar-
macokinetics monitoring will be performed as part of the
Phase I trial of the drug with a view to guiding dose escala-
tion. An important aspect of pharmacokinetically-guided
dosing is that pre-clinical and clinical studies should be com-
parable in terms of route and schedule. Initial phase I studies
with ICI D0490 will involve single dose intravenous bolus
administration.
In conclusion, these pharmacokinetic studies with ICI
D0490 have shown it to be an extremely stable immunotoxin.
Parallel pre-clinical studies, in the rat and a primate, support
this conclusion (Dr J. Lynch, personal communication). Thus
the clinical trial of ICI D0490, will represent an evaluation of
possibly the most persistent immunotoxin yet studied for the
therapy for cancer.
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